Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 5/20 | 0.40 |
| ▸ | LTA4H | P09960 | 3/20 | 0.40 |
| ▸ | ANPEP | P15144 | 2/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | ECE1 | P42892 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22503730 | 1.00 | MME (0.40) | MMELTA4HANPEPACEECE1 | |
| SCHEMBL5077777 | 1.00 | MME (0.40) | MMELTA4HANPEPACEECE1 | |
| Hydrochloric Acid SCHEMBL21724484 | 0.99 | MME (0.39) | MMELTA4HANPEPACEECE1 | |
| Hydrochloric Acid SCHEMBL21724486 | 0.99 | MME (0.39) | MMELTA4HANPEPACEECE1 | |
| SCHEMBL34470404 | 0.94 | MME (0.36) | MMELTA4HANPEP | |
| SCHEMBL29590996 | 0.92 | OPRD1 (0.36) | MMELTA4HANPEP | |
| SCHEMBL29794242 | 0.92 | MME (0.36) | MMELTA4HANPEPACEECE1 | |
| SCHEMBL29630414 | 0.92 | OPRD1 (0.36) | MMELTA4HANPEP | |
| SCHEMBL30799829 | 0.89 | GHSR (0.37) | — | |
| SCHEMBL10057501 | 0.89 | OPRD1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295762-A1 | COMPOSITE BIOACTIVE COMPOSITIONS AND APPLICATIONS THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2025-09-25 | — | — | US | claimed |
| WO-2025128968-A1 | AZA GLP-1-BASED THERAPEUTIC ANALOGUES | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2025-06-19 | — | — | WO | claimed |
| WO-2025123045-A1 | PREDICTIVE AND DIAGNOSTIC SCREENING METHODS FOR ENDOMETRIAL CANCER | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-06-12 | — | — | WO | claimed |
| US-20250108031-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES, LLC | 2025-04-03 | — | — | US | claimed |
| EP-3505533-B1 | SYNTHESIS METHOD FOR LOW-RACEMIZATION IMPURITY LIRAGLUTIDE | SHENZHEN JYMED TECH CO LTD (CN) | 2025-01-15 | — | — | EP | claimed |
| US-12053450-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-08-06 | — | — | US | claimed |
| US-12050228-B2 | Automated sample quality assessment | METABOLON, INC. (US) | 2024-07-30 | — | — | US | claimed |
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-07-02 | — | — | US | claimed |
| EP-4299134-A2 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | Bach Biosciences, LLC (US) | 2024-01-03 | — | — | EP | claimed |
| US-20230390409-A1 | FAP-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES | AVACTA LIFE SCIENCES LIMITED (GB) | 2023-12-07 | — | — | US | claimed |
| CN-113967258-A | FAP-activated therapeutics and uses related thereto | 塔夫茨大学信托人 | 2022-01-25 | — | — | CN | claimed |
| CN-113956325-A | FAP-activated therapeutics and uses related thereto | 塔夫茨大学信托人 | 2022-01-21 | — | — | CN | claimed |
| US-20210088539-A1 | AUTOMATED SAMPLE QUALITY ASSESSMENT | METABOLON, INC. | 2021-03-25 | — | — | US | claimed |
| US-10890592-B2 | Automated sample quality assessment | METABOLON, INC. (US) | 2021-01-12 | — | — | US | claimed |
| EP-0291626-A2 | Process for the preparation of optically-active cyanomethyl esters | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-11-23 | — | — | EP | claimed |
| US-4570017-A | Preparation of optically-active (mixed) anhydrides and acids | SHELL OIL COMPANY (US) | 1986-02-11 | — | — | US | claimed |
| US-4560515-A | NON-SYMMETRICAL KETENE REACTED WITH A-HYDROXYNITRILE; TERTUARY AMINE CATALYST | SHELL OIL COMPANY (US) | 1985-12-24 | — | — | US | claimed |
| US-4529810-A | Preparation of optically-active alpha-substituted carboxylic esters and acids | SHELL OIL COMPANY (US) | 1985-07-16 | — | — | US | claimed |
| EP-0116914-A1 | Preparation of optically-active alpha-substituted carboxylic esters and acids | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-08-29 | — | — | EP | claimed |
| EP-0109681-A2 | process for the preparation of optically-active cyanomethyl esters | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-05-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295762-A1 | COMPOSITE BIOACTIVE COMPOSITIONS AND APPLICATIONS THEREOF | BMP2, BMP1, MATR3 | MME 3208/4885LTA4H 1858/4885ANPEP 2730/4885 |
| US-20250108031-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | FAP, FIBP, GOT1 | MME 1245/4885LTA4H 963/4885ANPEP 93/4885 |
| US-20230390409-A1 | FAP-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES | FAP, FIBP, FUCA2 | MME 247/4885LTA4H 1296/4885ANPEP 32/4885 |
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | MME 1245/4885LTA4H 963/4885ANPEP 93/4885 |
| US-12053450-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | MME 1245/4885LTA4H 963/4885ANPEP 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.